Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature

Bibliographic Details
Title: Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature
Authors: Craig L. Slingluff, Paul R. Kunk, Joshua E. Reuss, Anne M. Stowman, Alejandro A. Gru, Elizabeth M. Gaughan
Source: Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)
Publisher Information: BMJ Publishing Group, 2016.
Publication Year: 2016
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Background We report a case of sarcoidosis in a patient with metastatic melanoma managed with combination ipilimumab/nivolumab. Sarcoid development has been linked with single agent immunotherapy but, to our knowledge, it has not been reported with combination ipilimumab/nivolumab treatment. This case raises unique management challenges for both the melanoma and the immunotherapy-related toxicity.Case presentation A 46 year old Caucasian female with M1c-metastatic melanoma was managed with ipilimumab/nivolumab combination. Patient experienced response in baseline lesions but developed new clinical and radiographic findings. Biopsy of new lesions at two different sites both demonstrated tumefactive sarcoidosis. Staining of the biopsy tissue for PD-L1 expression demonstrated strong PD-L1 staining of the histiocytes and lymphocytes within the granulomas. Monotherapy nivolumab was continued without progression of sarcoid findings or clinical deterioration.Conclusions Tissue biopsy for evaluation of new lesions on immunotherapy is an important step to help guide decision making, as non-melanoma lesions can mimic disease progression.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2051-1426
Relation: https://jitc.bmj.com/content/4/1/94.full; https://doaj.org/toc/2051-1426
DOI: 10.1186/s40425-016-0199-9
Access URL: https://doaj.org/article/3124a1d3ca5e4c1598b68d90fc08a3a5
Accession Number: edsdoj.3124a1d3ca5e4c1598b68d90fc08a3a5
Database: Directory of Open Access Journals
More Details
ISSN:20511426
DOI:10.1186/s40425-016-0199-9
Published in:Journal for ImmunoTherapy of Cancer
Language:English